Navigation Links
Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
Date:9/30/2008

BOSTON, Sept. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company intends to expand their current industry to include and capitalize on the $30 billion minimally invasive instrumentation market by implementing a business strategy. The Company's strategy is expected to substantially increase its revenue, and simultaneously increase its customer base.

Solos Endoscopy expects continuous growth in this market because physicians are developing new minimally invasive techniques, not only in the traditional area of general surgery, but also in other medical specialty areas. This shift in the Company's business strategy will allow many more procedures to be performed outside the operating room setting and this expansion creates an increased demand for high quality instrumentation in the medical product market.

"Our initiative for 2008 is to enhance the instrumentation that we have developed in the general surgery line, and to move our surgical instrument division into diverse specialties. We believe that we have a great future; our reputation in the medical industry is that we build excellent instruments and this, coupled with our new products, will significantly expand our revenue and customer base in the future," stated Robert Segersten, President of Solos Endoscopy, Inc.

For additional information on Solos Endoscopy, Inc. please visit http://www.solosendoscopy.com .

About Solos Endoscopy, Inc.

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com .

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
2. New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration
3. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
4. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
5. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
6. Covance Decides to Pursue Its Original Preclinical Strategy in China
7. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
8. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
9. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
10. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
11. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary Medicine ... experienced veterinary clients have treated over 100 of their own patients with the VetStem ... the highest level of care for their patients. , The veterinarians are Dr ...
(Date:5/20/2016)... ... ... The recent recall by Costco and Trader Joes of 47 million pounds ... 2016(1), demonstrates the need for faster and more cost effective bio-threat detection to ensure ... , PathSensor’s latest solution uses a biosensor technology called CANARY®. CANARY®, ...
(Date:5/19/2016)... May 19, 2016 There is ... recover given the relentless pressures in pricing and lack ... the investors circle though - numerous opportunities are up ... today,s session, ActiveWallSt.com,s presents four names in this sector: ... Pharmaceuticals Inc. (NASDAQ: VTAE ), Anthera Pharmaceuticals ...
(Date:5/19/2016)... - I dati saranno presentati ... 52 ° Congresso della Società ... - Le conclusioni dello studio indicano un tasso di ... cui il 90% presenta una d urata della risposta ... settantadue per cento dei pazienti ha riscontrato un beneficio clinico. ...
Breaking Biology Technology:
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
Breaking Biology News(10 mins):